Abstract
Oral paliperidone extended release (ER) [Invega®] has recently been approved for the treatment of schizophrenia in adolescents aged 15–17 years in the EU. The ER formulation of the drug provides consistent plasma drug concentrations, allowing convenient once-daily administration. In the subgroup of patients aged 15–17 years in clinical trials in adolescents aged 12–17 years with acute schizophrenia, paliperidone ER improved the symptoms and severity of schizophrenia, with improvements being maintained with longer-term treatment. Overall, paliperidone ER was generally well tolerated in adolescents, with a tolerability and safety profile similar to that in adults.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
